Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study
Main finding · Severe hypoglycaemiaResult — go to the resultHazard ratio 1.17 95% CI 0.91–1.50Authors' conclusion
In patients using second-generation sulphonylureas, fluoroquinolones were not associated with an increased risk of severe hypoglycaemia compared with amoxicillin. An increased risk among younger adults is possible.
Study context
- Population
- Patients who initiated second-generation sulphonylureas (1998–2020), UK Clinical Practice Research Datalink Aurum linked to hospitalization and vital statistics data
- Participants
- 143,417 patients
- Exposure
- Fluoroquinolones vs amoxicillin
- Fluoroquinolonesn = 13,123
- Amoxicillinn = 130,294reference
- Outcome
- Severe hypoglycaemia (hospitalization with or death because of hypoglycaemia)
- Follow-up
- 30 days
Methodological details1:5 matching on previous sulphonylurea use and propensity scores, intent-to-treat exposure definition
- 1:5 matching on previous sulphonylurea use and propensity scores
- Intent-to-treat exposure definition
Main finding
Severe hypoglycaemia
Hazard ratio
1.17
95% CI 0.91–1.50
Fluoroquinolonesvs Amoxicillin
HR 1.17 (95% CI 0.91–1.50)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Severe hypoglycaemia, age <65 yearsStratified analysis | 2.90 (1.41–5.97) | |
| Severe hypoglycaemia, age ≥65 yearsStratified analysis | 1.03 (0.79–1.35) | |
| 0.20.5125Hazard ratio (log scale) |
Effect modification by sex or HbA1c
- No evidence of effect modification by sex or HbA1c
Original publication
Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study. Diabetes Obes Metab. Published 2 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →